Suppr超能文献

口服西咪替丁对哮喘患者组胺和抗原诱导的支气管痉挛的影响。

Effect of orally administered cimetidine on histamine- and antigen-induced bronchospasm in subjects with asthma.

作者信息

Tashkin D P, Ungerer R, Wolfe R, Mendoza G, Calvarese B

出版信息

Am Rev Respir Dis. 1982 Jun;125(6):691-5. doi: 10.1164/arrd.1982.125.6.691.

Abstract

Previous studies concerning the effect of cimetidine, a histamine H2 receptor antagonist, on histamine- or antigen-induced bronchoconstriction have yielded conflicting results. Therefore, we examined the effects of cimetidine on sensitivity to both histamine- and antigen-induced bronchospasm in 12 subjects with mild asthma (baseline FEV1 greater than 70% predicted). Bronchial challenges with inhaled histamine or antigen were performed 2 h after a single dose of 300 mg cimetidine or placebo orally administered in a random, double-blind manner on separate days. The provocative concentration of antigen or histamine that produced a 20% decline in FEV1 from the postdiluent control value (PC20) was determined and log transformed. Plasma cimetidine concentrations 2 h after oral administration (mean, 1.5 microgram/ml; range, 0.9 to 2.4 mirograms/ml) were above the minimal concentration required for suppression of gastric acid secretion. No difference was noted in FEV1, specific airway conductance, or partial expiratory flow rates after cimetidine compared with that after placebo, indicating the lack of any bronchospastic effect of cimetidine in the absence of histamine or antigen challenge. However, mean log PC20 of histamine (but not of antigen) was significantly less after cimetidine than after placebo (p less than 0.05), indicating that cimetidine augmented histamine-(but not antigen-) induced bronchospasm. Four of 12 subjects exhibited a significant (greater than or equal to fourfold) decline in PC20 for histamine after cimetidine compared with that after placebo but no subject demonstrated a significant (greater than or equal to tenfold) decline in PC20 of antigen. No relationship was apparent between baseline sensitivity to histamine and cimetidine effect on histamine sensitivity in individual subjects. We conclude that in subjects with mild asthma, cimetidine in the usual recommended orally administered dose can increase sensitivity to bronchospasm induced by histamine but not by antigen. These findings suggest that cimetidine in this dose has a blocking effect on H2 receptors in airway smooth muscle but that this effect is not sufficient to alter the net impact of immunologic release of mediators on the airways.

摘要

先前有关组胺H2受体拮抗剂西咪替丁对组胺或抗原诱导的支气管收缩作用的研究结果相互矛盾。因此,我们在12名轻度哮喘患者(基线第一秒用力呼气量(FEV1)大于预测值的70%)中研究了西咪替丁对组胺和抗原诱导的支气管痉挛敏感性的影响。在不同日期以随机、双盲方式口服300mg西咪替丁或安慰剂单剂量2小时后,进行吸入组胺或抗原的支气管激发试验。测定使FEV1从稀释后对照值下降20%的抗原或组胺激发浓度(PC20)并进行对数转换。口服给药2小时后血浆西咪替丁浓度(平均1.5微克/毫升;范围0.9至2.4微克/毫升)高于抑制胃酸分泌所需的最低浓度。与安慰剂相比,西咪替丁给药后FEV1、比气道传导率或部分呼气流速无差异,表明在无组胺或抗原激发时西咪替丁无支气管痉挛作用。然而,西咪替丁给药后组胺(而非抗原)的平均对数PC20显著低于安慰剂(p<0.05),表明西咪替丁增强了组胺(而非抗原)诱导的支气管痉挛。12名受试者中有4名在西咪替丁给药后组胺PC20较安慰剂给药后显著下降(大于或等于四倍),但无受试者抗原PC20显著下降(大于或等于十倍)。个体受试者对组胺的基线敏感性与西咪替丁对组胺敏感性的影响之间无明显关系。我们得出结论,在轻度哮喘患者中,通常推荐的口服剂量西咪替丁可增加对组胺诱导的支气管痉挛的敏感性,但对抗原诱导的支气管痉挛无此作用。这些发现表明,该剂量的西咪替丁对气道平滑肌中的H2受体有阻断作用,但这种作用不足以改变介质免疫释放对气道的总体影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验